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Abstract: On 7 January 2020, researchers isolated and sequenced in China from patients with
severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide,
becoming a global health emergency. Typical manifestations consist of flu-like symptoms such as
fever, cough, fatigue, and dyspnea. However, in about 20% of patients, the infection progresses to
severe interstitial pneumonia and can induce an uncontrolled host-immune response, leading to a
life-threatening condition called cytokine release syndrome (CRS). CRS represents an emergency
scenario of a frequent challenge, which is the complex and interwoven link between infections and
autoimmunity. Indeed, treatment of CRS involves the use of both antivirals to control the underlying
infection and immunosuppressive agents to dampen the aberrant pro-inflammatory response of the
host. Several trials, evaluating the safety and effectiveness of immunosuppressants commonly used
in rheumatic diseases, are ongoing in patients with COVID-19 and CRS, some of which are achieving
promising results. However, such a use should follow a multidisciplinary approach, be accompanied
by close monitoring, be tailored to patient’s clinical and serological features, and be initiated at the
right time to reach the best results. Autoimmune patients receiving immunosuppressants could be
prone to SARS-CoV-2 infections; however, suspension of the ongoing therapy is contraindicated to
avoid disease flares and a consequent increase in the infection risk.
Keywords: SARS-CoV-2; COVID-19; rheumatoid arthritis; cytokine release syndrome; autoimmunity;
immunomodulation; tocilizumab; hydroxychloroquine; baricitinib
1. Introduction
On 7 January 2020, after a cluster of cases with pneumonia of unknown origin in Wuhan, Hubei, China,
researchers isolated a novel coronavirus, then called SARS-CoV-2 [1], and COVID-19, the induced disease.
SARS-CoV-2 is believed to have zoonotic origins (probably from the Huanan seafood market in Wuhan)
and has close genetic similarity (96%) to a bat coronavirus, suggesting it emerged from a bat-borne virus [2].
An intermediate animal reservoir such as the pangolin is also thought to be involved in its introduction to
humans, but efforts to identify intermediate hosts seem to have been unsuccessful [3,4]. Since the outbreak,
thanks to its contagiousness/virulence characteristics and boosted by globalization, SARS-CoV-2 moved
around the world faster than a virus has ever done before.
After three months since its appearance, it reached 1.5 × 106 infected patients, with 3.5 × 105
recovered patients and 100,000 deaths across the world [4]. Due to a number of unfortunate variables,
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Northern Italy was the first country outside of Asia affected by the rapid spreading of SARS-CoV-2,
which led, at the end of March, to the highest number of deaths worldwide [4]. Typical clinical
manifestations of the disease generally begin after less than 5–7 days of incubation and consist of fever,
cough, fatigue, and mild dyspnea.
However, data from China reported that about 15–20% of patients have severe disease with
interstitial pneumonia, which can progress to acute respiratory distress syndrome (ARDS) [5,6].
Pneumonia includes decreased oxygen saturation, with severe bilateral ground glass abnormalities,
patchy consolidation, and alveolar exudates [5,6]. In patients with ARDS, the virus can induce an
excessive and aberrant host immune response characterized by an upregulation of pro-inflammatory
cytokines, resembling the clinical and serological features of cytokine release syndrome (CRS). CRS is a
life-threatening emergency associated with high mortality; thus, an early identification is essential.
At the moment, there are no specific antiviral treatments recommended for SARS-CoV-2 and no vaccine
is currently available. A growing awareness of SARS-CoV-2 infection and CRS has led to exploring the use
of immunomodulatory drugs as a potential treatment for the management of these patients.
Here, the complex relationship between infections and autoimmunity in the emergency scenario
of the SARS-CoV-2 pandemic is discussed. We critically review the rationale for the adoption of
immunosuppressive agents, commonly used in autoimmune diseases, in the treatment of SARS-CoV-2
infection and report current knowledge of ongoing studies.
2. SARS-CoV-2 Infection and the Pathophysiology of Cytokine Release Syndrome
CRS is a systemic inflammatory life-threatening condition typically associated with biological
drug products, but also occurring during the response to some infections [7]. Initially described as
a reaction to the use of the anti-CD3 (OKT3) monoclonal antibody (mAb) [8], this syndrome is the
result of a cytokine storm. CRS has been under tight evaluation since it caused the admission to
the intensive care unit of six healthy individuals enrolled in the phase I trial for the anti-CD28 mAb
TGN1412A in 2006 [9]. CRS has been also observed in patients treated with immune checkpoint
inhibitors or T cell therapy (CAR T cells) [10]. It is noteworthy that the cytokine storm due to massive
T cell stimulation is also considered a relevant mechanism to the H5N1 influenza pathogenesis [11].
CRS and sepsis share several symptoms, and patients with CRS are at a high risk of infections, not only
for the immunosuppressive treatments, but likely also for the CRS-associated immune dysregulation
and tissue damages, especially at the mucosa barrier. Indeed, in CRS patients, infections principally
involve the respiratory tract.
The exacerbated reaction to infections or to biological therapy is caused by the rapid recruitment of
macrophages and neutrophils, which produce pro-inflammatory cytokines and alter the fragile balance
between a controlled immune response and a host-damaging reaction. Damaged tissues release molecules
normally not present outside the cells, including high-mobility group box 1 (HMGB1), ATP, uric acid,
and DNA, further amplifying inflammatory responses. All these molecules are part of the so-called
damage-associated molecular patterns (DAMPs). It is noteworthy that pathogen-associated molecular
patterns (PAMPs) and DAMPs are recognized by the same group of innate immunity receptors, namely
the pathogen recognition receptors (PRRs), which include toll-like receptors (TLRs), highly expressed in
neutrophils and macrophages. Engagement of TLRs and other PRRs leads to further activation of NF-kB
and the release of cytokines (IL-6, TNFα, IL-1, etc.) and other mediators of inflammation.
A relevant biological role has also been proposed for ferritin in CRS-related conditions, as well as
in autoimmune disease has been proposed. The presence of hyperferritinemia, indeed, is a well-known
feature in patients with different autoimmune conditions such as RA, systemic lupus erythematosus
(SLE), and anti-phospholipid syndrome [12]. It has been supposed that several mechanisms involving
the inhibition the H-ferritin-mediated suppression of immune cells may favor the loss of tolerance
and the onset of autoimmunity [13]. Ferritin can be also a pro-inflammatory signaling molecule,
and hyperferritinemia has been associated with different CRS-related conditions such as macrophage
activation syndrome (MAS) and septic shock [14].
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Ferritin could exert a pathogenic role in these diseases rather than being just the result of
hyperinflammation. In fact, ferritin synthesis is mediated, not only by iron availability, but also by
IL-1, IL-6, and TNF [15,16], which are overexpressed during CRS; on the other hand, it can induce the
expression of pro-inflammatory cytokines, thus becoming part of a vicious loop [17].
In particular, it has been hypothesized that during an ongoing infection, the signaling mediated
by bacterial/viral CpG DNA and TLR9 could activate the inflammasome, leading to IL-1 and IL-18
production [18–20]. Through DAMP signaling, infection could also increase the production of
hemoglobin [21] and activate macrophages, which are prominent producers of ferritin [22,23],
amplifying the inflammatory loop [23]. Moreover, a correlation between the serum levels of CD163,
a marker of macrophage activation [24], and ferritin in patients with MAS has been reported [25].
Different therapeutic approaches could be useful in blocking this pathway at different levels, such as
plasma exchange, intravenous immunoglobulins, or mAbs against IL-1 and IL-18 [18].
In patients affected by 2002/2003 SARS-CoV, immune dysregulation induced an abnormal
inflammatory cytokine production by alveolar macrophages with a concomitant T cell dysfunction,
involving both CD4 and CD8 T cells [26]. SARS patients with a more severe disease displayed higher
serum levels of pro-inflammatory cytokines (IFN-γ, IL-1, IL-6) and chemokines (including IL-8) [27].
In CRS, IFN-γ further activates immune cells, especially macrophages, which are induced to
produce more inflammatory cytokines and upregulate costimulatory ligands, feeding the harmful
positive loop of inflammation. It is important to remember that type I interferons (IFNs) play a critical
role in the normal/physiologic immune response to viruses by enhancing the toxic effects of CD8
T cells [28], activating NK cells, and restricting viral pathogenicity to the lung microenvironment.
IFNαR-deficient mice infected with the H5N1 or the 1918 influenza virus show indeed higher mortality
than wild-type mice, which display systemic dissemination of the virus [29]. It is noteworthy that
some studies showed that coronaviruses, in particular MERS-CoV, can suppress the expression of both
type I and type III IFNs, evading innate immune response and contributing to its pathogenicity [30].
In in vitro models, IFN-λ showed effects against 2002/2003 SARS-CoV and MERS-CoV, suggesting a
possible use to control viral infections by coronavirus. Interestingly, the expression of the type III IFN
receptors is more restricted to specific cell types (neutrophils and B cells) compared with type I IFN
receptors, a feature that could restrain inflammatory response to the (initial) site of infection. In an
animal model, treatment with IFN-λ2/IL-28A reversed the development of collagen-induced arthritis,
also indicating an anti-inflammatory role in autoimmune responses [31]. However, in the contest of
CRS associated with COVID-19, it cannot be excluded that type III IFN receptors are upregulated also in
other cell types and that these cytokines could also contribute to the complex pathogenic process [32].
In SARS-CoV-2 patients with a worse prognosis, IL-6, IL-10, and TNF-α quickly rise and reach high
levels. Conversely, in patients with milder symptoms, these cytokines reach lower levels, with their
expression rising and declining during the illness and recovery phase, respectively [33].
The production of IL-10, an anti-inflammatory cytokine, in the context of CRS is often
associated with the downregulation of neutrophil and monocyte function, a phenomenon termed
immunoparalysis [34]. Although conceptually beneficial, the persistent downregulation of HLA-DR
on monocytes, after sepsis, as well as after CRS, leads to higher mortality rates, suggesting that the
recovery from immunoparalysis is critical for patient survival [35].
As above mentioned, systemic cytokines are considered to be massively produced by macrophages
in SARS-CoV-2 patients [36]. However, also endothelial cells play a relevant role in CRS, not only as
cells that are damaged by pathogens and inflammatory responses, but also as co-culprits. Endothelial
cells indeed produce inflammatory cytokines, including IL-6, and upregulate adhesion molecules,
further promoting leukocytes’ recruitment and capillary leakage [37].
In line with lymphocyte recruitment into the place of infection/inflammation, two recent studies
showed that in patients with severe COVID-19, T cell lymphopenia is accompanied by an alteration in
the distribution of circulating T cell subpopulations; patients, indeed, have increased frequencies of
naive helper T cells and a reduction in memory helper T cells [38,39].
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The cytokine unbalance associated with the response to SARS-CoV-2 could also affect the effectiveness
of the immune response both in terms of viral clearance and future immune protection. For some of the
recovered patients, protective antibodies have been described. They are mainly directed towards the receptor
binding domain of the spike protein, and most likely, they interfere with viral entry [40]. Even if the majority
of patients recover, some of them after discharge from the hospital, asymptomatic and negative RT-PCR
viral RNA tests remain/return positive or even relapse [41]. Due to the limited number of described cases,
incomplete virus clearance rather than lack of protection cannot be ruled out. Noteworthy, previous studies
on 2002/2003 SARS-CoV showed heterogeneous results on B and T cell memory [42–44]. Information on the
long-term quality of immune response, T and B cell immunological memory, and long- versus short-lived
plasma cells towards SARS-CoV-2 is not available yet.
Altogether, these recent findings point to a major role of the host immune response, particularly
of CRS, as a determining co-factor in the severe life-threating form of COVID-19. Why some patients
develop an effective immune response, which is protective and not pathogenic, and why others
have a non-protective life-threatening immune response is a key question. It is likely that genetic
background, which is also involved in inflammatory responses, immune-mediated diseases (including
autoimmunity), and co-morbidities, may not only weaken the host, but also may share “common”
pathways in inflammatory damaging responses.
3. Anti-Host Therapy in SARS-CoV-2 Patients
Treatment of CRS involves the use of both antiviral agents to control the underlying infection and
immunosuppressants to lower the aberrant pro-inflammatory response of the host.
For a better understanding, it is essential to remind about the natural course of SARS-CoV-2 infection.
After the incubation period, indeed, the virus induces flu-like symptoms typical of mild disease; in
some patients, the infection can progress to interstitial pneumonia (moderate disease) or severe pneumonia
requiring oxygen therapy (severe disease), through to ARDS with respiratory failure [45]. This is probably the
moment at which the shift from a controlled immune response to a host-damaging reaction begins to manifest
clinically. Then, SARS-CoV-2 does not directly induce tissue damage, whereas the hyperinflammatory
immune activation of the host becomes the effective protagonist of the disease. The early identification of
this specific moment of transition is of key importance, to allow timely immunomodulatory intervention,
thus achieving a tailored approach and the best therapeutic effects (Figure 1).
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Figure 1. Use of anti-rheumatic immunosuppressive agents in COVID-19 patients, targeted to their 
immunomodulatory/antiviral activity and disease severity. Tocilizumab, sarilumab, and anakinra 
have the strongest immunosuppressive effect and have been already tested in cytokine release 
syndrome (CRS) (with tocilizumab being the only scheduled); thus, they should be administered in 
severe COVID-19 patients at the first manifestations of hyperinflammation. Baricitinib has both 
immunosuppressive effects (however, no data are available for CRS) and antiviral activity; thus, it 
could be adopted in the moderate/severe form of COVID-19. Hydroxychloroquine (HIQ) has antiviral 
properties and milder immunosuppressive activity than the other drugs; thus, it could be used in the 
moderate/severe form of COVID-19. 
To that end, several serologic markers have been proposed, such as the presence of 
thrombocytopenia, lymphopenia, and increased levels of D-dimer and ferritin [46]. 
Some authors have also reported a role for IL-6 and IL-10 in monitoring COVID-19 patients. In 
particular, significantly higher levels of IL-6 and IL-10 have been identified in severe COVID-19 
patients than in the milder forms, thus suggesting that these cytokines can be used to predict the 
transition from mild to severe infection [47]. 
4. Chloroquine and Hydroxychloroquine 
Hydroxychloroquine (HIQ) is an orally administered and low-cost drug widely used as a 
monotherapy in clinical rheumatological practice mainly to treat the mild form of rheumatoid 
arthritis (RA), SLE, and Sjogren’s syndrome patients, as well as in combination therapy with 
conventional immunosuppressants, in more severe patients. HIQ has a pleiotropic activity ranging 
from immunomodulatory effects, to anti-thrombotic action and antiviral properties. The 
immunomodulatory activity of HIQ has been demonstrated in vitro to be exerted by several 
mechanisms. 
HIQ interferes with lysosomal activity, impairing lysosomal and autophagosome functions and 
subsequently immune activation [48]. It can inhibit TLR-7 and TLR9 [49] signaling pathways and 
decrease the secretion of pro-inflammatory cytokines (IL-6, TNF-α, IL-1, IFN-γ) [50]. The anti-
thrombotic mechanism is still poorly clarified; anyway, it has been reported that it can reverse platelet 
activation and reduce anti-phospholipid (aPL) antibody titers in aPL patients [51]; it can also improve 
endothelial dysfunction and reduce the expression of adhesion molecules such as VCAM-1 and E-
selectin [52], mechanisms that could be relevant in severe COVID-19. 
Regarding the antiviral effects, it is known that HIQ is able to block the infection of different 
viruses, including SARS-CoV-1, by increasing endosomal pH and by interfering with the 
glycosylation of the cellular receptor [53,54].  
Figure 1. Use of anti-rheumatic immunosuppressive agents in COVID-19 patients, targeted to their
immunomodulatory/antiviral activity and disease severity. Tocilizumab, sarilumab, and anakinra have the
strongest immunosuppressive eff ct and have been alr ady tested in cytokine rel ase syndrome (CRS) (with
tocilizumab being the only scheduled); thus, they should be administered in severe COVID-19 patients at
the first anifestations of hyperinflammation. Baricitinib has both immunosuppressive effects (however, no
data are available for CRS) and antiviral activity; thus, it could be adopted in the moderate/severe form of
COVID-19. Hydroxychloroquine (HIQ) has antiviral properties and milder immunosuppressive activity
than the other drugs; thus, it could be used in the moderate/severe form of COVID-19.
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To that end, several serologic markers have been proposed, such as the presence of
thrombocytopenia, lymphopenia, and increased levels of D-dimer and ferritin [46].
Some authors have also reported a role for IL-6 and IL-10 in monitoring COVID-19 patients.
In particular, significantly higher levels of IL-6 and IL-10 have been identified in severe COVID-19
patients than in the milder forms, thus suggesting that these cytokines can be used to predict the
transition from mild to severe infection [47].
4. Chloroquine and Hydroxychloroquine
Hydroxychloroquine (HIQ) is an orally administered and low-cost drug widely used as a
monotherapy in clinical rheumatological practice mainly to treat the mild form of rheumatoid
arthritis (RA), SLE, and Sjogren’s syndrome patients, as well as in combination therapy with
conventional immunosuppressants, in more severe patients. HIQ has a pleiotropic activity ranging from
immunomodulatory effects, to anti-thrombotic action and antiviral properties. The immunomodulatory
activity of HIQ has been demonstrated in vitro to be exerted by several mechanisms.
HIQ interferes with lysosomal activity, impairing lysosomal and autophagosome functions
and subsequently immune activation [48]. It can inhibit TLR-7 and TLR9 [49] signaling
pathways and decrease the secretion of pro-inflammatory cytokines (IL-6, TNF-α, IL-1, IFN-γ) [50].
The anti-thrombotic mechanism is still poorly clarified; anyway, it has been reported that it can reverse
platelet activation and reduce anti-phospholipid (aPL) antibody titers in aPL patients [51]; it can also
improve endothelial dysfunction and reduce the expression of adhesion molecules such as VCAM-1
and E-selectin [52], mechanisms that could be relevant in severe COVID-19.
Regarding the antiviral effects, it is known that HIQ is able to block the infection of different
viruses, including SARS-CoV-1, by increasing endosomal pH and by interfering with the glycosylation
of the cellular receptor [53,54].
Several in vitro studies have been conducted to explore its efficacy in blocking SARS-CoV-2
infection. Chloroquine was found to inhibit the virus at a low micromolar concentration, with a half
maximal effective concentration (EC50) of 1.13 µM and a half cytotoxic concentration (CC50) greater
than 100 µM, which can be achievable with the standard dosing regimen [55]. In a recent study, HIQ
was found to have a higher antiviral effect than chloroquine, with a lower EC50 [56].
As a consequence of these encouraging results, at least 23 clinical trials are being carried out to
evaluate the efficacy and safety of chloroquine or HIQ in the treatment of SARS-CoV-2 patients [57].
By now, the results have demonstrated efficacy in reducing the exacerbation of pneumonia, improving
lung imaging findings, and promoting a virus-negative conversion without serious adverse events [58].
A guideline document promoted by the Italian Society of Infectious and Tropical Disease recommends
the use of chloroquine 300 mg × 2/day or HIQ 200 mg x 2/day, in patients presenting with mild
respiratory symptoms and comorbidities, as well as in patients with severe respiratory failure [59].
5. IL-6 Inhibitors
IL-6 is a pleotropic cytokine with several immunological activities. It plays a role in the
differentiation of mature B cells into plasma cells, and combined with TGF-β, it induces the
differentiation of naive CD4 positive T cells into Th17-cells and induces the production of acute-phase
proteins such as CRP, fibrinogen, serum amyloid A, and hepcidin [60,61]. In bone marrow, IL-6 induces
the maturation of megakaryocytes into platelets and the activation of hematopoietic stem cells [60,61].
Tocilizumab and sarilumab are a humanized and human mAb, respectively, recognizing the
soluble and membrane-bound forms of the IL-6 receptor. They are part of the first line biological therapy
in patients with moderately to severely active RA and juvenile idiopathic arthritis; more recently,
tocilizumab has been scheduled also for giant cell arteritis patients [61].
It is of note that IL-6 in combination with TGF- β is also produced by fibroblasts and activated
macrophages exerting a pro-fibrotic effect at different sites such as lungs, skin, and liver [61].
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In a recent work, we proposed tocilizumab as a valid therapeutic strategy in patients with
interstitial pneumonitis associated with RA, because it might contrast the pro-fibrotic effects of IL-6,
ameliorating both the articular and lung involvement [62]; this observation was recently confirmed
by other authors [63]. As reported above, in some patients, SARS-CoV-2 infection can induce an
uncontrolled and aberrant host hyperimmune response that is associated with lung damage and fibrosis,
leading to life-threatening multi-organ failure. Serologically, an increase in the serum concentrations
of IL-1, IL-6, IL-2, IL-7, IL-10, TNF-α, granulocyte colony-stimulating factor, interferon-γ-inducible
protein 10, monocyte chemoattractant protein 1, and macrophage inflammatory protein 1-α has been
found [64–66]. Furthermore, different Chinese authors reported that a lower lymphocyte count and
elevated CRP, ferritin, D-dimer, and IL-6 were poor prognostic factors in SARS-CoV-2 patients [67].
The efficacy of tocilizumab in resolving life-threatening CRS during CAR T cell therapies was
assessed in small patient cohorts [7]; however, the striking positive results led to its rapid approval for
the treatment of CRS by the FDA in 2017 followed by EMA in 2018 [68,69]. Based on these data, small
retrospective studies on patients affected by severe COVID-19 demonstrated that tocilizumab improved
CT scan ground glass lesions and oxygen saturation, normalized CRP levels, and lymphocyte count in
a significant percentage of patients [70,71].
IL-6 inhibitors should be initiated at the early stages of hyperinflammation, after discussion
between critical care medicine and hematology/rheumatology and infection specialists; one additional
dose may be considered if clinical deterioration persists (max two doses per course in severe
SARS-CoV-2) [72,73].
A multicenter randomized clinical trial (RCT) of tocilizumab has been approved in China
and is currently ongoing in patients with SARS-CoV-2 pneumonia and elevated IL-6 levels
(ChiCTR2000029765).
Several clinical trials on the use of tocilizumab in patients with COVID-19 are already posted on
ClinicalTrials.gov. These trials are enrolling different sets of the COVID-19 population ranging from
patients with recent onset pneumonia to life-threatening-associated CRS.
There is also heterogenicity among the primary outcomes, but those mainly used are the proportion
of subjects with normalization of fever and oxygen saturation at 14 days, the proportion of patients
requiring mechanical ventilation and intensive care unit (ICU) admission, and the one-month mortality
rate. The increase in lymphocyte count, decrease in CRP, and amelioration of CT lung opacity are
frequently reported secondary endpoints (NCT04317092).
Another five trials have been posted on ClinicalTrials.gov on the use of sarilumab in COVID-19
patients, three of which have started recruitment. Two studies are enrolling hospitalized COVID-19
patients aiming at evaluating the safety and effectiveness of low or high dose i.v. sarilumab
(NCT04315298; NCT04327388). The other study is recruiting patients with moderate/severe pneumonia
associated with SARS-CoV-2, and the primary endpoint is the survival without the need for ventilator
utilization at Day 14 (NCT04324073).
6. IL1-Inhibitors
In addition to IL-6, also IL-1 plays an important role in CRS [74,75]. IL-1β and IL-1α increase
acute-phase signaling, homing of immune cells to the site of primary infection and epithelial cell
activation, both inducing the production of many other cytokines [75,76]. IL-1β can also drive
proinflammatory activity in the respiratory tract as shown by its presence in the bronchoalveolar lavage
fluid of patients with lung injury [76].
Anakinra is a 17 kD recombinant, non-glycosylated human IL-1Ra that blocks IL-1α and IL-1β.
It was approved for treating RA, cryopyrin-associated periodic syndromes, and Still’s disease [77].
It has been reported to be safe and effective in the management of sepsis-associated MAS,
in particular those with increased liver enzymes, hypofibrinogenemia, and thrombocytopenia [78].
Conversely, the other anti-IL1β inhibitor, canakinumab, has not been demonstrated to be beneficial in
MAS [79]. As of now, four clinical trials are recruiting patients with COVID-19, severe acute respiratory
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failure, and CRS, aiming at evaluating the safety and effectiveness of anakinra alone or in combination
with anti-IL-6 agents (NCT04330638, NCT0432402, NCT04357366, NCT04339712).
7. JAK-STAT Inhibitors
Janus kinase inhibitors, also known as JAK inhibitors, are a class of orally administered targeted
synthetic immunosuppressants that act by inhibiting the activity of one or more of the JAK family
members (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway. Several
inflammatory cytokines, involved in autoimmunity diseases, by binding to their receptors, initiate a
JAK dependent phosphorylation cascade constituting the signaling pathway of gene transcription.
Hence, drugs that inhibit the activity of JAK block cytokine signaling.
These inhibitors have therapeutic application in the treatment of cancer, RA, psoriasis, psoriatic
arthritis, and inflammatory bowel diseases [80].
By now three JAK inhibitors are approved for the treatment of rheumatic conditions, tofacitinib,
baricitinib, and upadacitinib. Tofacitinib is a specific inhibitor of JAK3 and to a lesser extent JAK1
and JAK2. Baricitinib reversibly inhibits JAK1 and JAK2, with moderate activity against TYK2 and
significantly less against JAK3, whereas upadacitinib is a selective inhibitor of JAK1 [81].
Pharmacology studies, in vitro, demonstrated that all three anti-JAK antibodies can inhibit
JAK1/2-dependent cytokines (IL-6 and IFN-γ) and the JAK1/TYK2-dependent cytokines (IL-10 and
IFN-α), whereas tofacitinib and upadacitinib are the most potent inhibitors of the JAK1/3-dependent
cytokines (IL-2, IL-4, IL-15, and IL-21) [81]. Considering the above data, the adoption of these drugs for
CRS management could be useful. Indeed, preclinical studies on murine models of Hemophagocytic
lymphohistiocytosis (HLH) and MAS showed the efficacy of JAK inhibition [82,83].
JAK inhibitors have also gained the attention of researchers in the scenario of SARS-CoV-2 infection,
for their demonstrated antiviral properties. Most viruses enter cells through receptor-mediated
endocytosis. One of the known regulators of endocytosis is the AP2-associated protein kinase 1
(AAK1); thus, AAK1 inhibitors can interrupt the passage of the virus into cells and can be helpful in
preventing virus infections [84]. Among AAK1 inhibitors, baricitinib has shown the highest affinity,
being able to inhibit AAK1 at the standard therapeutic dosage for RA [85]. Furthermore, the use of
baricitinib appears to be particularly safe also in combination with antiviral drugs considering its
minimal interaction with the CYP drug-metabolizing enzymes [86]. Tofacitinib showed no detectable
inhibition of AAK1, whereas no data are yet available on the effect of upadacitinib on AAK1 [87].
Currently an Italian trial is recruiting patients with mild to moderate SARS-CoV-2 infection
(NCT04320277). Patients will be treated with a combination of baricitinib and antiviral therapy with
ritonavir. The primary endpoint of the trial is the percentage of patients requiring transfer to ICU as
compared with the rate of transfers observed in controls. Another European trial is starting recruitment
of patients with moderate to severe SARS-CoV-2 infection; baricitinib will be used in monotherapy
compared to lopinavir/ritonavir, HIQ, and IL-6 inhibitor (NCT04321993), all administered alone.
8. TNF-α Inhibitors
TNF-α belongs to a large family of cytokines known as the TNF superfamily. It is produced
mainly by activated macrophages, NK, T, and B cells, and exerts its action through two receptors called
TNFR1 and TNFR2. After binding to its receptors, TNF-α leads to a myriad and often conflicting
effects reflecting complex cross-talk mechanisms [88]. It can mediate both apoptosis and cell activation,
proliferation of B cells, and enhancement of cytotoxic activity of NK cells. The NF-κB activation
pathway following TNF-α binding also induces the production of pro-inflammatory cytokines such
as IL-4, IL-6, and IL-8, leading to extensive tissue damage such as vascular leakage and lung injury
seen in many chronic inflammatory diseases [89,90]. As for IL-6, TNF-α is responsible for systemic
inflammatory manifestations such as fever and cachexia and has been shown to be a central cytokine
in the activation and maintenance of CRS [75]. TNF-α is a potent antiviral cytokine that acts directly
by killing the virus-infected cells prior to maximal virus replication. However, it is known that the
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viral spike protein of SARS-CoV-2 is able to induce a TNF-α-converting enzyme (TACE)-dependent
shedding of the ACE2 ectodomain, which is coupled to TNF-α production and is crucial for the
penetration of the virus into the cell [90,91]. Based on these observations, TNF-α appeared to be an
attractive therapeutic target. Treatment of MAS patients with etanercept (a fusion protein made from
the combination of two soluble human 75k TNF-R linked to an Fc portion of an IgG1) has already been
described, but data are scarce and contradictory [92,93]. A trial evaluating the efficacy and safety of
adalimumab (human mAb directed against TNF-α) in SARS-CoV-2 patients with severe respiratory
failure and CRS has recently been registered in the Chinese Clinical Trial Registry (ChiCTR2000030089).
9. Other Potential Immunological Therapeutic Options
9.1. B Cell Inhibitors
Rituximab (RTX) is a chimeric anti-CD20 mAb, approved for the treatment of B cell malignancies,
RA, and ANCA-associated vasculitis [94–96].
B cell ablation with rituximab has been observed to have efficacy in macrophage activation
syndrome in patients with underlying Epstein-Barr virus (EBV) [97]. The proposed mechanism is the
reduction of viral load via destruction of the reservoir of EBV-infected cells. Unfortunately, RTX therapy
has been shown to induce CRS, probably caused by the rapid destruction of tumor cells and consequent
changes of serum cytokine levels [98]. It seems that CRS is a side effect of RTX therapy considering that
it occurs mainly in patients with a very high tumor burden. Thus, its use appears not to be indicated in
CRS secondary to SARS-CoV-2 infection.
9.2. T Cell Modulation Therapy
CRS occurring during SARS-CoV-2 infection has a clinical and serological profile resembling that
of secondary HLH. Given the central role of CD8 T cells in secondary HLH, non-ablative inhibitors of
T cell function are also attractive therapeutic choices [74].
Cyclosporine (CyS) is a cyclic undecapeptide that binds intracellularly to cyclophilin and
suppresses calcium-dependent phosphatase calcineurin pathway activation. Functional consequences
are the block of T cell survival and activation and inhibition of IL-2 production [99,100].
It is used for the prevention of transplant rejection, as well as in different autoimmune conditions
such as RA, psoriasis, and glomerulonephritis [101]. It has already been adopted as part of the standard
protocol in familiar HLH patients [102].
It could also be relevant to underline that CyS is able to inhibit in vitro the function of a
transmembrane protein called P-glycoprotein that pumps out of the cell several drugs, including
amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir, thus being crucial in the development
of drug resistance to anti-retroviral therapy. CyS has also been demonstrated to revert in vivo drug
resistance to methotrexate in RA and Psoriatic Arthritis (PsA) patients [103,104].
On the basis of the anti-inflammatory activity and its ability to improve the effectiveness of
antiviral therapy, low dose CyS in combination with antiviral drugs might be rational in selected
patients without severe renal involvement.
Abatacept is a dimeric fusion protein composed of the human CTLA-4 extracellular domain and a
human FcIgG1 that binds with high-affinity CD80/CD86 molecules, thus impairing T cell activation
and T-B cell cross-talk during the immune response [103,105]. It is scheduled for use in RA and more
recently PsA patients. Abatacept has been proposed as a valid option for interstitial lung disease
associated with RA in several case series [106] and has already been proven in a few cases of MAS
refractory to standard intervention, demonstrating mild effectiveness and safety [107].
The main data on the use of anti-rheumatic drugs currently tested in clinical trials of COVID-19
patients are resumed in Table 1.
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Table 1. Anti-rheumatic immunological drugs currently tested in clinical trials of COVID-19 patients.
Hydroxychloroquine/Chloroquine Tocilizumab/Sarilumab Anakinra Baricitinib Adalimumab
Mechanism
of Action
Immunomodulation = Impairing lysosomal functions
Antiviral = Increasing endosomal pH and interfering
with cellular receptors
Immunomodulation = IL-6 inhibition Immunomodulation =
IL-1 inhibition
Immunomodulation = IL-6 and
IFN-γ inhibition
Antiviral = AAK1 inhibition
Immunomodulation =
TNF-α inhibition
Target Population Mild with comorbidity
Moderate/severe
Moderate/severe with or without CRS Severe and CRS Mild to severe, with or without CRS Severe and CRS
Main Therapeutic Regimen HIQ = 200–400 mg/day/orally
CQ = 300 mg × 2/day/ orally
Single infusion 8 mg/kg/i.v.
(max 800 mg)
Second cycle after 8–12 h if no significant response **
100 mg/day/sc or
100 mg/4 times a day/i.v.
2–4 mg/day/orally Not reported
Main Safety Exclusion Criteria Consider drug-to-drug interactions
(i.e., QT interval prolongation)
Retinopathy
Severe renal dysfunction






Active TB and infections
other than COVID-19
NYHA class III/IV Severe
renal dysfunction
Pregnancy










Specific Parameters to Closely
Monitor
Blood count (reduction in
Neut and Plt),
AST, ALT, procalcitonin *,
IL-6
Blood count,
AST, ALT, procalcitonin *
Blood count,
AST, ALT, procalcitonin *
Blood count,
AST, ALT, procalcitonin *
* To exclude active infections from sources other than COVID-19; ** sarilumab is being studied also at 11 mg/kg/i.v.; both tocilizumab and sarilumab are being tested also s.c. CRS =
cytokine release syndrome, Plt = platelets, Neut = neutrophils, ALT = alanine transferase, AST= aspartate transferase, i.v. = intravenous, s.c. = subcutaneous, HIQ = hydroxychloroquine,
CQ= chloroquine.
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10. Autoimmunity and SARS-CoV-2 Infection
As previously stated, SARS-CoV-2 infection represents an emergency scenario of an old challenge,
which is the complex and interwoven link between infections and autoimmunity. This complex link
has implications at the biological level in terms of individual susceptibility/resistance, as well as in the
delicate balance to be reached with therapeutic options. Polymorphisms in the HLA locus have been
shown to affect individual susceptibility with variants that confer resistance to some viral infections
and predispose to autoimmune diseases and others that show more complex associations increasing the
risks for both autoimmunity and infections [108]. Susceptibility to several infectious diseases including
HIV, hepatitis B, and influenza is associated with specific HLA haplotypes. For instance, HLA-A*11,
HLA-B*35, and HLA-DRB1*10 have been shown to correlate with susceptibility to influenza A (H1N1)
infection. It would be important therefore to understand if specific HLA loci are associated with
susceptibility to SARS-CoV-2 or to the development of a protective immune response. While it is still
early to have information on SARS-CoV-2 and HLA, studies on 2002/2003 SARS-CoV did not show
associations with HLA-A, HLA-B, and HLA-DRB1 allele frequencies [109], whereas some variants of
HLA-DRB1 seem to correlate with susceptibility to MERS [110]. Noteworthy, some HLA-DRB1 amino
acid variants are associated with RA, conferring either susceptibility or resistance to this disease [108].
Patients with autoimmune diseases are, indeed, at high risk of infections, due to endogenous
(dysfunctional immune system) and external factors (i.e., immunosuppressants).
In RA patients, the risk for infections is about double with respect to healthy individuals, and they
are mainly located at the bone and joints, skin, soft tissues, and respiratory levels [111]. In RA, patient
data on infection risk generally show that methotrexate (the gold standard immunosuppressants for
inflammatory arthritis) and HIQ are the therapies impacting the least in the increased susceptibility
to infection, both being considered relatively safe [112,113]. The risk of infections observed in RA
patients treated with biologic drugs is generally reported to be higher compared with patients receiving
conventional immunosuppressants [114,115]. In a retrospective observational cohort-study, our group
evaluated the role of methotrexate, corticosteroids, and TNF-α antagonists alone or in combined
therapy on non-serious and serious infections in RA and spondyloarthritis (SpA) patients. We identified
an incidence ratio/100 patient-years of 36.3 for all infections, being 34.9 for non-serious and 1.4 for
serious infections [116]. These results are similar to those reported from the CORRONA Register
on a larger RA U.S. patient population [117]. As confirmed by other authors, we also found that
the combination of anti-TNF-α with corticosteroids was the most pro-infective treatment, whereas
methotrexate alone was relatively safe [116–119].
The corticosteroids/anti-TNF-α combination can indeed synergize in lowering TNF-α levels
through different and independent mechanisms, with the consequent increase of the anti-inflammatory
effect, but at the expense of a rise in the risk of infection [118,119]. As reported by metanalyses
and real-life studies, among biological agents, abatacept seems to be the safest in terms of infectious
risk [120,121]. Autoimmune diseases and infections are already linked with alteration in disease activity.
In autoimmune patients, indeed, infections may induce disease flare-up that may be followed by
a severe clinical course, representing a frequent cause of death (20–55%) [122].
On the other hand, it is known that a higher disease activity is associated with a higher probability
of developing infections [117]. In fact, high disease activity is the result of chronic inflammation against
self, which can exhaust the immune resources and deviate the immune response from the danger
signals delivered by pathogens [123]. Conversely, infections may stimulate the immune system, thus
leading to a reactivation of the underlying autoimmune disease.
In view of the above, it is not surprising that, although autoimmune patients under
immunosuppressive agents could be prone to SARS-CoV-2 infections, suspension of the ongoing
conventional and biological therapy is contraindicated to avoid disease flares with a consequent
increased risk of infection [124].
It could be hypothesized that the impairment of immune response caused by the ongoing therapy
could be a double-edged sword. On the one hand, indeed, immunosuppression increases the risk
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and consequently the prevalence of SARS-CoV-2 infections in autoimmune patients, but on the other
hand, it could decrease the risk of the aberrant hyperinflammatory response seen in patients with
SARS-CoV-2. A registry of COVID-19 in autoimmune patients has been created by the Italian Society
of Rheumatology. This registry could give useful information to clarify the above hypothesis and be
of crucial help for therapeutic decision-making in this particular group of patients. Whatever these
results will show, one should keep in mind that co-infection can often be lethal, and thus, the use
of anti-influenza and anti-pneumococcal vaccinations, already recommended in these patients [125],
assumes even more importance in this new scenario of the COVID-19 pandemic.
11. Conclusions
Several trials evaluating the safety and effectiveness of immunosuppressants commonly used in
autoimmune patients are ongoing in patients with COVID-19 and CRS, some of which are achieving
promising results. However, such a use should follow a multidisciplinary specialist approach, be
accompanied by close monitoring, be tailored to patient’s clinical and serological features, and be
initiated at the right time to reach the best results. It is also important to take into account that
these drugs, pivotal in the treatment of many autoimmune patients, are already running out; in
fact, shortages are being reported from several European countries (i.e., i.v. tocilizumab and HIQ).
Autoimmune patients under immunosuppressive drugs could be prone to SARS-CoV-2 infection;
however, suspension of the ongoing conventional and biological therapy is contraindicated to avoid
disease flares and the consequent increase in the infection risk.
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